NervGen Pharma Corp. (NGEN)vsRevolution Medicines Inc (RVMD)
NGEN
NervGen Pharma Corp.
$2.01
+5.24%
HEALTHCARE · Cap: $197.54M
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
NGEN
Avoid16
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NGEN
NGEN has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : NGEN
The primary concerns for NGEN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
NGEN is growing revenue faster at 0.0% — sustainability is the question.
NGEN generates stronger free cash flow (-8M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 16/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
NervGen Pharma Corp. (NGEN) is an innovative biotechnology company focused on addressing unmet medical needs in the field of neurodegenerative diseases through its proprietary platform, which leverages nerve regeneration technology. The company is committed to the research and development of novel therapeutics aimed at restoring nerve function and improving patient outcomes for conditions like multiple sclerosis and spinal cord injuries. With a strategic emphasis on advancing its clinical programs and enhancing its intellectual property portfolio, NervGen is well-positioned to capitalize on the growing demand for effective treatments in the neurology sector, fostering potential long-term growth and value creation for investors.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?